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Dr adhesins are expressed on the surface of uropathogenic
and diffusely adherent strains of Escherichia coli. The major
adhesin subunit (DraE/AfaE) of these organelles mediates
attachment of the bacterium to the surface of the host cell and
possibly intracellular invasion through its recognition of the
complement regulator decay-accelerating factor (DAF) and/
or members of the carcinoembryonic antigen (CEA) family.
The adhesin subunit of the Dr haemagglutinin, a Dr-family
member, additionally binds type IV collagen and is inhibited
in all its receptor interactions by the antibiotic chloram-
phenicol (CLM). In this study, previous structural work is built
upon by reporting the X-ray structures of DraE bound to two
chloramphenicol derivatives: chloramphenicol succinate (CLS)
and bromamphenicol (BRM). The CLS structure demon-
strates that acylation of the 3-hydroxyl group of CLM with
succinyl does not signiﬁcantly perturb the mode of binding,
while the BRM structure implies that the binding pocket is
able to accommodatebulkier substituents on the N-acylgroup.
It is concluded that modiﬁcations of the 3-hydroxyl group
would generate a potent Dr haemagglutinin inhibitor that
would not cause the toxic side effects that are associated with
the normal bacteriostatic activity of CLM.
Received 12 December 2008
Accepted 12 February 2009
PDB References: DraE–CLS,
space group C2, 2w5p,
r2w5psf; DraE–CLS, space
group P3, 2jkn, r2jknsf;
DraE–BRM, 2jkl, r2jklsf;
DraE–THM, 2jkj, r2jkjsf.
1. Introduction
Dr adhesins are thought to be important virulence factors
for diffusely adherent (DAEC) and uropathogenic (UPEC)
strains of Escherichia coli. Members of the Dr adhesin family
include the Dr haemagglutinin, Dr-II, Afa-III and F1845
ﬁmbriae (Servin, 2005). Estimates as to the frequency of Dr-
family members in DAEC isolates range from 50% to 75%
(Giron et al., 1991). They are also the third most common
group of colonization factors for UPEC behind type 1 and P
pili (Nowicki et al., 2001), with 25–50% of cystitis isolates from
children and 30% of pyelonephritis isolates in pregnant
women expressing Dr adhesins (Labigne-Roussel & Falkow,
1988). In addition, infection with Dr adhesin-positive UPEC is
associated with an increased risk of a recurrent urinary-tract
infection (Foxman et al., 1995).
The Dr haemagglutinin, a member of the Dr adhesin family,
can utilize up to four receptors to adhere to the host. The
major adhesin subunit DraE recognizes decay-accelerating
factor (DAF; Bernet-Camard et al., 1996) and members of the
carcinoembryonic antigen (CEA) family (Guignot et al., 2000,
2009) and can trigger the bacterial mobilization of  5 1
integrin (Guignot et al., 2009). DraE also binds type IV
collagen (Westerlund et al., 1989; Carnoy & Moseley, 1997).
Together, these interactions are capable of orchestrating someof the host effects that are associated with the DAEC and
UPEC pathotypes (reviewed by Servin, 2005).
The receptor interactions of DraE are inhibited by the
antibiotic chloramphenicol (CLM). CLM inhibition of DraE
was serendipitously discovered by Nowicki et al. (1988), who
noticed that a CLM-contaminated reagent completely abol-
ished DAF-mediated mannose-resistant haemagglutination
(MRHA). CLM also inhibits the type IV collagen and CEA
receptor interactions (Westerlund et al., 1989; Korotkova,
Cota et al., 2006). In the years following the Nowicki group
discovery, CLM was found to compare very effectively with
other inhibitors of bacterial adhesion, its minimum inhibitory
concentration (MIC) being 2 mM compared with equivalent
MICs for type 1 and P pili (carbohydrate) receptor analogues
of between 400 and 500 mM (Old, 1972; Svenson et al., 1983).
More recently, however, novel classes of carbohydrate deri-
vatives have been developed with afﬁnities in the nanomolar
range speciﬁcally for type 1 or P pili (Bouckaert et al., 2005;
Ohlsson et al., 2005). The present work represents a ﬁrst ex-
ploratory step towards CLM-based, less toxic and perhaps
more speciﬁc inhibitors of DraE-mediated bacterial adhesion.
For example, chloramphenicol succinate (CLS) inhibits DAF-
mediated MRHA at similar levels to CLM (Nowicki et al.,
1988), although the stability of CLS to hydrolysis has not been
characterized and the molecule is likely to be quickly meta-
bolized to CLM in vivo.
The Dr haemagglutinin is the only CLM-sensitive Dr
adhesin-family member (Le Bouguenec et al., 1993). Our
recently determined X-ray structure of the DraE–CLM com-
plex has uncovered the molecular basis of the speciﬁcity of
CLM for DraE (Pettigrew et al., 2004). Binding was observed
to be dependent on a shallow hydrophobic depression on the
surface of DraE deﬁned by residues Pro40–Pro43 on strand B
and Ile111, Gly113 and Tyr115 on strand E. The structure of
AfaE-III (Anderson et al., 2004), a close relative of DraE with
98% sequence identity (three residue differences out of 140),
demonstrates that the mutation of residue 88 from threonine
(DraE) to methionine (AfaE-III) is sufﬁcient to mask the
binding pocket, thereby abolishing CLM sensitivity.
The conventional bacteriostatic activity of CLM arises from
its ability to act as an inhibitor of the 50S prokaryotic ribo-
some (Moazed & Noller, 1987). In this context, the principal
requirements for CLM activity are the 1,3-propanediol moiety
and a para-substituted electron-withdrawing (nitro) group on
the aromatic ring (Nagabhushan et al., 1991). The structure of
CLM complexed with the 50S ribosome of Deinococcus
radiodurans has demonstrated that CLM inhibits protein
biosynthesis in prokaryotes by binding to the peptidyl trans-
ferase active site (Schlunzen et al., 2001). This interaction is
particularly dependent on the burial of the nitrobenzene
group and on hydrogen-bonding interactions between the
primary hydroxyl group (3-OH) of CLM and ribosomal RNA.
In contrast, our X-ray structure of the complex between DraE
and CLM demonstrates that this CLM interaction is somewhat
different in character, being more dependent on the hydro-
phobic burial of the dichloromethyl group of CLM rather than
the aromatic ring or the hydroxyl groups (Pettigrew et al.,
2004). Since CLM is toxic in a small number of susceptible
individuals, owing to its ability to traverse cell membranes and
inhibit mitochondrial ribosomes (Kroon & Van den Bogert,
1983), we proposed that the DraE–CLM structure could
provide a starting point for the design of an agent designed to
inhibit Dr adhesion without the toxic side effects that are
associated with the ‘normal’ bacteriostatic activity of CLM.
In the present study, a number of CLM derivatives were
designed, cocrystallized with DraE and examined using X-ray
crystallography in order to unambiguously determine which
functional groups are important for DraE binding. We present
the structures of chloramphenicol succinate and brom-
amphenicol bound to DraE and use them to suggest possible
modiﬁcations to the small molecule that could result in a safer
inhibitor with a more wide-ranging action against other Dr
adhesin-family members.
2. Materials and methods
2.1. Protein expression and purification
Recombinant DraE was expressed as an N-terminal hexa-
histidine fusion in Escherichia coli strain M15[pREP4]
(Qiagen) and puriﬁed as described previously (Pettigrew et al.,
2004). Brieﬂy, DraE was puriﬁed from the supernatant using
nickel-afﬁnity chromatography, followed by size-exclusion
chromatography on an Superdex S75 Sepharose column (GE
Life Sciences) to separate the trimeric form from small
amounts of monomeric, dimeric and aggregated forms. The
trimeric form was concentrated to 1.6 mg ml
 1 and used in
crystallization trials. Although the DraE trimer has previously
been shown to be an artefact resulting from ‘domain swap-
ping’ of strand A1 (rather than strand G, as observed in native
Dr ﬁmbriae), the chloramphenicol-binding site is intact in this
form of the protein (Pettigrew et al., 2004). This construct is
amenable to crystallization in a number of different crystal
forms, which makes it a convenient route to determining a
number of CLM-derivative–DraE cocrystal structures.
2.2. Synthesis
The various CLM derivatives and their abbreviations are
summarized in Fig. 1. Chloramphenicol succinate (CLS),
chloramphenicol base (CLB) and thiamphenicol (THM) were
obtained from commercial sources (Sigma–Aldrich, UK). All
the other analogues were synthesized as described below.
All reactions involving moisture-sensitive reagents were
carried out in a nitrogen atmosphere using standard vacuum-
line techniques and glassware that was ﬂame-dried and cooled
under nitrogen before use. The solvents were dried according
to the procedure outlined by Grubbs and coworkers (Pang-
born et al., 1996). Water was puriﬁed using an Elix UV-10
system. All other solvents were used as supplied (analytical or
HPLC grade) without prior puriﬁcation. Thin-layer chroma-
tography was performed on aluminium plates coated with
60F
254 silica. The plates were visualized using UV light
(254 nm), iodine, 1% aqueous KMnO4 or 10% ethanolic
phosphomolybdic acid. Melting points were recorded on a
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Optical rotations were recorded on a PerkinElmer 241
polarimeter with a water-jacketed 10 cm cell. Speciﬁc rota-
tions are reported in 10
 1 deg cm
2 g
 1 and concentrations (c)
in grams per 100 ml. NMR spectra were recorded on Bruker
Avance spectrometers in the deuterated solvent stated. The
ﬁeld was locked by external referencing to the relevant
deuteron resonance.
2.2.1. N-Propyl 2,2-dichloroacetamide (NPDA).T oa
stirred solution of 1-aminopropane (0.70 ml, 8.5 mmol) in
CH2Cl2 (30 ml) at 273 K was added a solution of dichloro-
acetyl chloride (0.81 ml, 8.5 mmol) in CH2Cl2 (20 ml) drop-
wise. The resulting solution was stirred at 273 K for 1 h and
then at room temperature (RT) for 2 h. The solution was
washed successively with saturated aqueous NaHCO3 (10 ml),
saturated aqueous NaCl (10 ml), dried (MgSO4) and the
solvent removed with a vacuum pump (in vacuo). The crude
product was recrystallized from ethyl acetate/pentane to yield
the title compound as a white crystalline solid (1.16 g, 80%):
melting point (m.p.) 321–323 K [literature melting point (lit.
m.p.) 322–323 K; Matsumura et al., 1976];  H (400 MHz,
methanol-d4) 0.96 (3H, t, J = 7.5 Hz, CH3), 1.53–1.62 (2H, m,
CH2CH3), 3.22 (2H, t, J = 7.1 Hz, CONHCH2), 6.24 (1H, s,
COCHCl2).
2.2.2. (1000R,2000R)-2,2-Dibromo-N-[1000,3000-dihydroxy-1000-(40000 0 0-
nitrophenyl)propan-2000-yl]acetamide (bromamphenicol/BRM).
To a stirred solution of dibromoacetic acid (0.21 ml, 2.3 mmol)
in tetrahydrofuran (THF, 20 ml) under N2 at 273 K was added
triethylamine (0.32 ml, 2.3 mmol) and then trimethylacetyl
chloride (0.28 ml, 2.3 mmol) dropwise. The resulting suspen-
sion was stirred at 273 K for 1 h. The supernatant solution was
decanted and added dropwise to a stirred solution of (1R,2R)-
2-amino-1-(40-nitrophenyl)propane-1,3-diol (490 mg, 2.3 mmol)
at 273 K. The resulting solution was stirred at 273 K for 1 h
and then RT for 2 h and was then quenched with saturated
aqueous ammonium chloride (5 ml). The organic phase was
separated and the aqueous phase was extracted with ethyl
acetate (2   20 ml). The combined organic extracts were
washed successively with saturated aqueous NaHCO3 (10 ml)
and saturated aqueous NaCl (10 ml), dried (MgSO4) and the
solvent was removed in vacuo. The crude product was puriﬁed
by recrystallization from methanol/diethyl ether to give the
title compound as a white crystalline solid (590 mg, 62%): m.p.
321–323 (lit. m.p. 325–326 K; Moersch, 1955); [ ]D
22 +22.4
(c 1.0, EtOH) {lit. [ ]D
25 +19.6 (c 1.0, EtOH) (Moersch, 1955)};
 H (400 MHz, methanol-d4) 3.62 [1H, dd, J = 10.8, 6.0 Hz,
C(30)H2A], 3.83 [1H, dd, J = 10.8, 7.4 Hz, C(30)H2B], 4.12–4.16
[1H, m, C(20)H], 5.19 [1H, d, J = 2.3 Hz, C(10)H], 6.19 [1H, s,
C(1)H], 7.67 [2H, d, J = 8.4 Hz, Ar(200)H and Ar(600)H], 8.20
[2H, d, J = 8.4 Hz, Ar(300)H and Ar(500)H].
2.2.3. (1000R,2000R)-N-[1000,3000-Dihydroxy-1000-(40000 0 0-nitrophenyl)pro-
pan-2000-yl]isobutyramide (methamphenicol/MEM). To a stirred
solution of (1R,2R)-2-amino-1-(40-nitrophenyl)propane-1,3-
diol (500 mg, 2.4 mmol) in THF (20 ml) at 273 K was added
triethylamine (0.33 ml, 2.4 mmol) and then a solution of iso-
butyryl chloride (0.25 ml, 2.4 mmol) in THF (20 ml) dropwise.
The resulting solution was stirred at 273 K for 1 h and then RT
for 2 h. The solvent was removed in vacuo and the residue was
taken up in ethyl acetate (30 ml). The solution was washed
successively with 10% aqueous HCl (10 ml), saturated
aqueous NaHCO3 (10 ml), saturated aqueous NaCl (10 ml),
dried (MgSO4) and the solvent was removed in vacuo.T h e
crude product was recrystallized from ethyl acetate/pentane to
yield the title compound as a white crystalline solid (450 mg,
68%): m.p. 301–303 K (lit. m.p. 304.5–306 K; Shirahata et al.,
1972); [ ]D
22  56.4 (c 1.1, EtOH) {lit. [ ]D
25  61 (c 1.0, EtOH)
(Shirahata et al., 1972)};  H (400 MHz, methanol-d4) 0.89 (3H,
d, J = 6.9 Hz, CHMe2), 1.01 (3H, d, J = 6.8 Hz, CHMe2), 2.39–
2.48 (1H, m, CHMe2), 3.61 [1H, dd, J= 10.8, 5.9 Hz, C(30)H2A],
3.81 [1H, dd, J = 10.8, 7.4 Hz, C(30)H2B], 4.19–4.23 [1H, m,
C(20)H], 5.18 [1H, d, J = 2.6 Hz, C(10)H], 7.66 [2H, d,
J = 8.5 Hz, Ar(200)H and Ar(600)H], 8.21 [2H, d, J = 8.5 Hz,
Ar(300)H and Ar(500)H].
2.3. Crystallization
Cocrystallization of a number of CLM-analogue–DraE
complexes was attempted using a crystallization robot (Tecan,
Zurich, Switzerland) to generate a large number of ammo-
nium sulfate concentration versus small-molecule concentra-
tion grid screens at pH 7.0 (0.1 M Na HEPES).
DraE–CLS cocrystals in space group P3 were obtained in
2 M ammonium sulfate, 0.1–20 mM CLS and 0.1 M Na
HEPES pH 7.0. One unique crystal crystallized in space group
C2 in a drop containing 10 mM CLS but could not be repro-
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Figure 1
Chloramphenicol derivatives studied.duced. Owing to the low solubility of bromamphenicol (BRM)
and thiamphenicol (THM), soaks of these small molecules
into preformed CLS cocrystals were also attempted. CLS
cocrystals were transferred to a mother-liquor solution with-
out CLS and left for 15–20 min to reduce the occupancy of the
small molecule in the binding site. Longer backsoaking, which,
in principle, would have been needed to soak the ligand out
(Collins et al., 2007), led to visible damage to the crystals and
could not be afforded. The crystal was then placed in a
mother-liquor solution saturated with either BRM or THM
and soaked for a further 15 min.
2.4. Data collection and processing
X-ray diffraction data were collected in-house and on
beamline ID-29 at the European Synchrotron Radiation
Facility (ESRF). Crystals were cryoprotected in 25% ethylene
glycol plus mother liquor or soaking solution before being
mounted in a ﬁbre loop and ﬂash-frozen at 100 K. The data-
reduction and reﬁnement statistics are summarized in Table 1.
Two crystal forms were obtained for successful CLM-deriva-
tive–DraE cocrystals: trigonal (P3) and monoclinic (C2).
Within MOSFLM (Collaborative Computational Project,
Number 4, 1994), initial autoindexing solutions based on two
sets of ﬁve diffraction images (’ =9 0   apart) were used to
screen for successful small-molecule-bound derivatives. Crys-
tals that initial indexing revealed as belonging to the orthor-
hombic polymorph deposited as PDB entry 1ut1 (space group
P212121,unit-cellparametersa=68.88,b=108.51,c=119.62A ˚ )
were immediately discarded as packing interactions make the
CLM-binding site inaccessible in this crystal form; these
crystals must therefore form by favouring the subunit–subunit
interaction over the subunit–ligand interaction and are useless
for the present study. Prior to the start of the DraE–BRM data
collection, an X-ray ﬂuorescence scan was taken to locate the
bromine peak absorption wavelength (0.91947 A ˚ ). Data were
collected at this wavelength to maximize the anomalous
difference signal from the Br atoms of BRM. Data reduction
was performed using SCALA (Evans, 2006). The Friedel pairs
were kept separate for the BRM data set and were merged for
the others.
2.5. Structure solution and refinement
2.5.1. P3 data sets. Reﬁnement of the CLM-derivative data
sets in space group P3 (CLS, BRM and THM) were performed
using the program autoBUSTER (Vonrhein et al., 2006). As
the unit-cell parameters (a = b = 119.6, c = 57.8 A ˚ ) and
symmetry were those of our
previously determined crystal
structure of the DraE–CLM
complex (space group P3;
a = b = 119.0, c = 57.4 A ˚ ; PDB
code 1usq), this model, minus
CLM, was used as a starting point
for reﬁnement. The binding site
was excluded from the automatic
addition of waters. The small-
molecule conformation was then
interpreted from an Fo   Fc map
after all the other density had
been explained. For each CLM
derivative, the program CORINA
(Sadowski et al., 1994) was used to
generate a coordinate ﬁle with
appropriate bond lengths and
angles. The program XPLO2D
(Kleywegt & Jones, 1997) was
used to generate a TNT stereo-
chemical restraints dictionary
from the resulting coordinate
ﬁle. Soft noncrystallographic
symmetry (NCS) restraints were
then used in reﬁning the atomic
positions and temperature factors
of the six NCS-related copies of
the CLM derivative.
For the CLS–DraE data set in
space group P3, an NCS-averaged
2Fo   Fc density map was
produced after the CLS molecule
research papers
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Table 1
Data-reduction and reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
DraE–CLS.1 DraE–CLS.2 DraE–BRM DraE–THM
PDB code 2w5p 2jkn 2jkl 2jkj
Data statistics
Beamline ID14-3 ESRF In-house ID29 ESRF In-house
Space group C2 P3 P3 P3
Unit-cell parameters (A ˚ ,  ) a = 118.9, b = 68.6,
c = 62.1,   = 111
a = b = 119.3,
c = 57.7
a = b = 119.6,
c = 57.8
a = b = 119.6,
c = 57.7
Resolution (A ˚ ) 59–1.9 (2.0–1.9) 30–1.9 (2.0–1.9) 25–1.9 (2.0–1.9) 25–2.3 (2.4–2.3)
No. of unique reﬂections 33359 60758 72802 43763
Redundancy 4.1 3.3 6.7 4.3
Completeness (%) 96.8 (78.1) 98.2 (97.7) 100 (100) 100 (99.9)
Anomalous completeness N/A N/A 99.9 (100) N/A
Rmerge 0.10 (0.38) 0.07 (0.21) 0.10 (0.24) 0.10 (0.33)
Ranom N/A N/A 0.04 (0.11) N/A
Average I/ (I) 6.0 (2.0) 4.6 (2.1) 5.2 (3.0) 8.9 (2.2)
No. of molecules in ASU 3 6 6 6
Reﬁnement statistics
R (%) 20.4 (21.0) 19.0 (19.3) 17.9 (18.1) 24.9 (27.8)
Rfree (%) 23.6 (24.5) 21.2 (22.3) 20.0 (19.7) 27.3 (30.7)
No. of residues/atoms in model
No. of protein atoms 3211 6314 6323 6289
No. of nonprotein atoms 393 972 1095 391
Mean B, protein (A ˚ 2)2 6 2 2 1 6 1 5
Mean B, nonprotein [mean B
small molecule] (A ˚ 2)
37 [33] 36 [45†] 32 [35] 27 [32]
No. of sulfates/ethylene
glycols/small molecules
3/0/6 12/12/6 14/11/8 15/0/8
Geometry
R.m.s.d. bonds (A ˚ ) 0.006 0.009 0.004 0.003
R.m.s.d. angles ( ) 0.8 0.9 0.8 0.7
Residues in
Most favoured regions (%) 85.7 84.9 84.2 82.5
Additionally allowed regions (%) 14.0 14.9 15.8 17.5
Generously allowed regions (%) 0.3 0.0 0.0 0.0
Disallowed regions (%) 0.0 0.1 0.0 0.0
† This value includes atoms in the multiple conformations of the succinate tail.had been built and reﬁned in the absence of the succinate tail,
since the succinate moiety was not visible in the initial
difference map. The coordinates of the small molecule and the
binding site (comprised of residues 37–45, 84–88 and 110–116)
were used to deﬁne a 5 A ˚ radius mask around the atoms using
the program NCSMASK (Collaborative Computational
Project 4, Number 4, 1994). The NCS operators and the mask
were used as input for the program MAPROT (Collaborative
Computational Project 4, Number 4, 1994) to produce the
NCS-averaged 2Fo   Fc density map. Three conformers for
the succinate tail, each at an occupancy of 0.3, were built. 15
cycles of manual (NCS-restrained) BUSTER-TNT reﬁnement
with all six copies of CLS in place generated three energy-
minimized succinate conformers.
For the BRM data set in space group P3, an anomalous
difference map was calculated using the phases from the ﬁnal
reﬁned model in the absence of small molecule. Inspection of
this map unambiguously conﬁrmed that the small-molecule
density was a superposition of CLS and BRM. After the initial
placement of CLS (minus the succinate tail) and BRM into the
Fo   Fc map (each at 50% occupancy), an occupancy reﬁne-
ment of the small molecules determined the relative compo-
sition of each binding site. The small-molecule parameters
were allowed to reﬁne independently of NCS restraints as
each binding site had a different occupancy.
2.5.2. C2 data set. Initial phases for the CLS data in space
group C2 were determined by searching with the DraE–CLM
trimer in MOLREP, again with the CLM molecules omitted.
12 cycles of (monomer) rigid-body reﬁnement were run using
BUSTER-TNT (Blanc et al., 2004) with no nonbonded
restraints. Next, autoBUSTER was used to reﬁne the model
with soft NCS restraints and to add waters. After four rounds
of rebuilding and reﬁnement using XtalView/Xﬁt and
BUSTER-TNT, respectively, the Fo   Fc map was inspected to
conﬁrm the presence of CLS in the binding site.
3. Results
Previously, we reported the structure of DraE bound to CLM
(Pettigrew et al., 2004). In this structure, CLM binding was
observed to be focused on the chlorine ‘tail’ rather than the
nitrobenzene ‘head’ of the molecule. The presence of CLM in
the crystallization mother liquor results in a change of space
group from the apo orthorhombic (P212121) crystal form to the
‘drug-bound’trigonal (P3) crystal forms. This is a consequence
of the binding site being involved in a crystal contact in the
orthorhombic crystal form (see x3.4 below for details of this
crystal contact).
In the present work, a number of CLM analogues were
tested in order to determine which functional groups of CLM
are important for DraE interaction (Fig. 1). Cocrystals were
very difﬁcult to obtain for most of the small molecules owing
to their extremely poor aqueous solubility, while soaks of the
required CLM derivative into pre-formed CLM/CLS cocrys-
tals were complicated by residual CLM/CLS in the binding
site. Therefore, this route to structure determination was only
attempted for small molecules with easily identiﬁable func-
tional groups (such as the anomalous scatterers of BRM or the
para-substituted methyl sulfone group of THM).
All the cocrystals described in this work belong to the P3
form (with the exception of a single irreproducible C2 DraE–
CLS crystal that grew in 10 mM CLS); both C2a n dP3 crystals
contain DraE trimers, as did the apo P212121 crystals (and the
related AfaE-III cubic and trigonal crystals). The physio-
logical intersubunit interactions that give rise to the adhesin
ﬁbres in vivo are those described in the published NMR study
of DraE (Anderson et al., 2004), while the crystals contain
strand-swapped trimers (Pettigrew et al., 2004): as explained in
the latter study, the trimers in these crystals arise from inter-
subunit strand swapping and have no physiological relevance,
but the nonphysiological intersubunit strand swapping does
not affect the CLM ligand binding as it occurs at a site distal
with respect to the site of ﬁbre and trimer formation. This was
proved by the NMR chemical shift mapping upon CLM
titration, which agreed with the CLM-binding site of the
crystal structures and was conducted on the donor-strand
exchanged DraE construct that does not give rise to trimers
(Pettigrew et al., 2004). Also entirely crystal-related and
therefore of no physiological relevance is the intertrimer non-
crystallographic symmetry that describes the packing of the
trimers; for this reason, we do not describe the packing nor the
noncrystallographic symmetry in detail (sufﬁce here to say
that in both crystal forms the trimers are arranged in slabs
laying in the ab planes and are stacked along the c direction,
both the a and c unit-cell axes being of similar length in the
two forms; see Table 1).
3.1. N-Propyldichloroacetamide and chloramphenicol base
The observed mode of CLM binding to DraE suggested that
the interaction is focused on the burial of the chlorines. In
order to investigate this in more detail, two CLM fragments
consisting of the aliphatic ‘tail’ (N-propyldichloroacetamide;
NPDA) and the aromatic ‘head’ (chloramphenicol base; CLB)
groups were studied (Fig. 1). Unfortunately, NPDA abolished
the crystallization of DraE at small-molecule concentrations
greater than 0.1 mM and only the apo crystals were obtained
for lower concentrations. This could imply that NPDA bound
in the CLM-binding pocket. In this scenario, crystallization
would be abolished by the inability of the small molecule to
stabilize the appropriate crystal contacts in the trigonal crystal
form. Alternatively, NPDA may have bound nonspeciﬁcally to
the protein, thereby perturbing crystal contacts elsewhere.
Crystallization mother liquors containing CLB at concentra-
tions of up to 1 mM generated the apo orthorhombic crystal
form. Since the concentration of CLB did not appear to
inﬂuence the crystallization of the apo crystal form, we con-
cluded that CLB did not interact speciﬁcally with the CLM-
binding site or nonspeciﬁcally with a portion of DraE that was
involved in a crystal contact. This hypothesis is supported by
the observation that CLB is unable to inhibit the haemag-
glutination of erythrocytes (Nowicki et al., 1988).
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In order to establish whether substitution at the primary
hydroxyl of CLM inﬂuences the binding of the small molecule
to DraE, the structure of a DraE–CLS complex was deter-
mined. CLS cocrystals in space group P3 were reproducibly
obtained using small-molecule concentrations between 1 and
15 mM. In this crystal form, the unbiased Fo   Fc difference
map showed CLM-like density in the region of the physio
logical binding site (Fig. 2a). The aliphatic ‘tail’ and the nitro-
benzene ‘head’ group were traced within this electron density.
Positional and temperature (B) factor reﬁnement conﬁrmed
that CLS was present in the binding site at full occupancy, with
an average B factor of 32 A ˚ 2. No difference density was
resolved for the succinate tail, implying that these atoms
adopted a number of alternate conformers that were not
resolved at 1.9 A ˚ resolution. However, an NCS-averaged
2Fo   Fc map revealed weak density for three possible
low-energy succinate conformers (Fig. 2b). With each
conformer set to an occupancy of 30%, the B factors reﬁned to
an average value of 49 A ˚ 2 for the succinate atoms, compared
with an average value of 40 A ˚ 2 for the rest of the small
molecule.
Aunique CLS cocrystal in space group C2 was obtained at a
small-molecule concentration of 10 mM and could not be
reproduced. In this crystal form, the unbiased Fo   Fc map
revealed density for the dichloroacetyl moiety of CLS in the
physiological binding site (Fig. 2c). However, even after
temperature-factor and occupancy reﬁnement with the di-
chloroacetyl group in place, density for the nitrobenzene head
group was not visible in any of the NCS-related binding sites.
Ordering of the whole ligand in the P3 forms is helped by
crystal contacts from a neighbouring protein molecule (Gln47
and Leu49) to the ligand atoms C7 and C8 (in the phenyl ring)
and one of the O atoms on the nitro moiety (the atom labelled
O9B); this crystal contact is missing in the C2 form and the
‘head group’ of CLS adopted a number of conformations that
were not traceable. Overall, the CLS–DraE complex struc-
tures imply that (i) substitutions at the primary hydroxyl do
not signiﬁcantly affect the mode of CLM binding and (ii) the
nitrobenzene group is not required to bind DraE.
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Figure 2
The physiological ligand-binding site. (a, b, c) Maps and models for chloramphenicol succinate: the reﬁned model of CLS is shown [with the succinate tail
ini (b) and without it in (a)]. (a) Unbiased Fo   Fc map (data set DraE–CLS.2) contoured at 2.5  showing the CLS density in the hydrophobic pocket (P3
crystal form). (b) The NCS-averaged 2Fo   Fc electron density in the binding pocket (P3 crystal form, averaged over all six copies of the density in the
ASU) reveals three possible lowest energy conformers for the succinate tail. (c) Unbiased Fo   Fc map (blue mesh, data set DraE–CLS.1) contoured at
2.3 , showing that in the C2 crystal form the aromatic head group and the succinate tail are disordered. (d) The same view as in (a) for the BRM
derivative, with the unbiased Fo   Fc difference map (contoured at 2.2 ) shown as a blue mesh. (e) Anomalous difference map (purple mesh) for the
BRM derivative calculated in the resolution range 25–1.9 A ˚ using phases from the protein model only (contoured at 3.5 ). It clearly reveals the presence
of two bromines in the CLM-binding site. The ﬁnal reﬁned BRM model (20% occupancy) is also shown. The ﬁnal reﬁned CLS model is not shown for
reasons of clarity, but it adopts an identical conformation. Figures were rendered in PyMOL (DeLano, 2004).3.3. Bromamphenicol and methamphenicol
To investigate the contribution of the aliphatic tail to the
small-molecule interaction, attempts were made to cocrys-
tallize DraE with methamphenicol (MEM; less hydrophobic
than CLM) and BRM (more hydrophobic than CLM) (Fig. 1).
MEM was tested at comparable concentrations to CLM (up to
1m M). Despite this, only the apo crystal form was obtained.
Therefore, the reduced size and hydrophobicity of the acetyl
group of MEM relative to the dichloroacetyl group of CLM
signiﬁcantly reduced or abolished the DraE–small molecule
interaction. BRM was nearly insoluble and even saturated
BRM mother liquors were unable to produce anything other
than the apo crystal form. At such negligible BRM concen-
trations it was impossible to reach any conclusions about the
relative afﬁnities of BRM and CLM for DraE.
BRM soaks into CLS cocrystals were performed and the
anomalous signal of the bromines was exploited in order to
unambiguously determine the location of the small molecule.
The ﬂuorescence scan showed a clear absorption edge in the
region of the K absorption edge of bromine (data not shown).
This conﬁrmed that some BRM had been dissolved despite the
low solubility of the molecule. The anomalous difference map
revealed two peaks in the density at a position in the
physiological binding site that was previously seen to be
occupied by the chlorines of CLM/CLS (Fig. 2e). The f00 value
for chlorine is low at the wavelength used in the experiment
(0.26 compared with 3.82 for bromine at 0.91947 A ˚ ). Hence,
the anomalous difference peaks in the binding site must arise
from the presence of the bromines of BRM. In addition, the
unbiased Fo   Fc difference map showed CLM-like density in
the same region (Fig. 2d). The entire BRM molecule was
traced within this map. However, BRM did not reﬁne at full
occupancy, as strong negative residual peaks were observed in
the region of the two bromines. After occupancy reﬁnement of
BRM, strong positive residuals were observed for all the
small-molecule atoms except for the bromines. Therefore, the
binding pocket contained a superposition of CLS and BRM in
identical orientations. Repeated rounds of alternating occu-
pancy and positional reﬁnements revealed that BRM and CLS
were present at between 20–30% and 50–70% occupancy,
respectively, in the six NCS-related copies of the binding site.
This structure demonstrated that the binding pocket of DraE
can accommodate larger chemical groups.
The anomalous difference map revealed two bromines at a
secondary BRM-binding site which was deﬁned by the inter-
face between two copies of DraE. The small molecule bridged
a crystal contact, but the area of contact between molecules is
too small for it to be of signiﬁcance (300 A ˚ 2; 3.8% of the
monomer’s surface); this second binding site was therefore
assumed to be an artefact of crystal packing. Moreover, CLM
inhibition has been mapped to the area of surface close to the
main binding site (Pettigrew et al., 2004); henceforth, this site
is referred to as the ‘nonphysiological’ binding site. The
2Fo   Fc and unbiased Fo   Fc maps in this region showed
electron density corresponding to the dibromoacetyl moiety of
BRM (data not shown). Difference density for the 1,3-
propanediol moiety was only resolved after reﬁnement of the
dibromoacetyl group. Even after reﬁnement with the aliphatic
‘tail’ in place, the aromatic ‘head’ group could not be resolved
in the 2Fo   Fc map or the Fo   Fc map. This implied that the
aromatic group adopted a number of alternate conformers
that could not be resolved at 1.9 A ˚ resolution. The average
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Figure 3
The nonphysiological THM-binding site. (a)T h e2 Fo   Fc map contoured at 1.3  (calculated after reﬁnement of the entire THM molecule) in the region
of the nonphysiological binding site clearly shows the tetrahedral density of the sulfonyl group. (b) LIGPLOT (Wallace et al., 1995) representation of
THM at the same site. The number of each residue involved is given, together with the chain designation of the DraE subunit it originates from (D or F).
An identical THM-binding site is also observed between copies B and C.temperature factor of the BRM fragment was 33 A ˚ 2,
suggesting that the nonphysiological BRM-binding site was
fully occupied. As an entire THM molecule was found in an
identical orientation in the same nonphysiological binding site,
the relevant protein–small molecule contacts are discussed
below. Fig. 3 illustrates this second binding site and the
orientation of the ligand in it.
3.4. Thiamphenicol
Preparation of THM–DraE cocrystals was attempted in
order to determine whether para substitutions of the nitro
group affected the interaction with DraE. The aromatic ‘head’
group of THM comprises a para-substituted methyl phenyl
sulfone moiety (Fig. 1). Soaks of THM into CLS cocrystals
were attempted based on the assumption that the tetrahedral
methyl sulfone group of THM could be distinguished from the
planar nitro group of CLS in the electron density.
Inspection of the unbiased Fo   Fc difference density in the
region of the physiological binding pocket revealed a planar
rather than a tetrahedral group at the para position of the
benzene ring (data not shown). Indeed, CLS reﬁned success-
fully at full occupancy and no residual peaks were observed in
the difference map. Therefore, we concluded that THM was
unable to enter the CLM-binding pocket of DraE in the P3
crystal form. Steric interference between the protein and the
methylsulfonyl group of THM is the most likely reason for
this.
As mentioned above, THM occupied the same nonphysio-
logical binding site as BRM. 2Fo   Fc and Fo   Fc maps were
calculated using phases from the protein, the CLS models in
the physiological binding site and the dichloroacetyl group of
THM in the nonphysiological binding site. The para-substi-
tuted tetrahedral moiety of THM was clearly observed in the
nonphysiological binding site in both density maps. The entire
THM molecule was traced within
this difference density and no
negative peaks were observed in
the difference map after reﬁne-
ment with 100% THM occupancy
(Fig. 3). The average B factor
(33 A ˚ 2) was comparable to the
average nonprotein B factor
(27 A ˚ 2). Therefore, the two
nonphysiological binding sites in
the ASU were fully occupied.
The principal contacts between
THM and the protein are given in
Fig. 3. The two THM molecules in
the ASU adopt a similar confor-
mation to CLM in the physio-
logical binding site and are
positioned at the interface
between two subunit copies. In
Fig. 3 this is illustrated by subunits
D and F (in the crystal the same
binding site exists between the
subunits labelled B and C). This predominately electrostatic
interaction is mediated by residues within the loop between
the ﬁrst and third strand on one subunit (labelled D in Fig. 3)
and by residues within a loop between the sixth and ninth  -
strand on the other (labelled F). In more detail, hydrogen
bonds are formed between the carbonyl of THM and the
main-chain amide of Val105, the primary hydroxyl group
OH(3) of THM forms hydrogen bonds to the side-chain atoms
of Asp104 on one subunit (chains F and C) and Thr36 on the
other (chains D and B), and a hydrogen bond occurs between
the main-chain carbonyl of Gly33 and the amide within the
aliphatic tail of THM. Van der Waals contacts are also formed
between atoms of the aliphatic tail and residues within both
DraE subunits. Only minor van der Waals contacts are
observed between the para-substituted methyl phenyl sulfone
moiety and the protein.
4. Discussion
There is an urgent need for novel therapeutics to combat
the emergence of antibiotic-resistant strains of pathogenic
bacteria (Breithaupt, 1999). An attractive approach is the use
of agents that interfere with the ability of the bacterium to
adhere to the host. As adhesion is an absolute requirement for
successful colonization, prevention of adhesion at an early
stage should prevent infection. Furthermore, since anti-
adhesive agents do not kill or inhibit bacterial growth, it is
expected that strains which are resistant to these agents will
emerge at a much lower rate than those which are resistant to
antibiotics (Ofek et al., 2003). Studies on anti-adhesives for
UPEC have focused on the use of carbohydrate-receptor
analogues, which aim to competitively inhibit bacterial adhe-
sion via the lectin domains of type 1 and P pili (reviewed by
Sharon, 2006). As UPEC strains express more than one type
of adhesin (Hacker, 1992), any therapeutic cocktail against
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Figure 4
Receptor-binding sites on DraE. Solvent-accessible surface representation of a single DraE subunit,
together with the location of CLM. Residues which have been reported to be important for DAF (red),
collagen (blue and purple) and CLM (purple) binding are coloured (Van Loy et al., 2002; Carnoy &
Moseley, 1997). Note: Asp52 has not been implicated in collagen binding. The asterisk marks the site of the
secondary nonphysiological THM and BRM binding.UTIs must include an effective agent against Dr adhesins. One
lead candidate is the antibiotic chloramphenicol (CLM),
which abolishes the adhesion of the Dr haemagglutinin DraE
to DAF, CEA and type IV collagen (Nowicki et al., 1988;
Westerlund et al., 1989). All the derivatives of CLM studied
here are expected to inhibit ﬁmbrial adhesion in the same way
as CLM does, given that they bind at the same site and that
CLM binding at that site has previously been shown to disturb
receptor adhesion (Pettigrew et al., 2004).
4.1. Substitution at the primary hydroxyl of CLM does not
perturb binding
The CLS structure in space group P3 proves that substitu-
tions at the primary hydroxyl 3-OH do not affect the mode of
CLM binding to DraE. In contrast, the 3-hydroxyl group
is essential for ribosome inhibition; both chloramphenicol
phosphotransferase and chloramphenicol acetyltransferase
abolish the bacteriostatic activity of CLM by phosphorylation
(Mosher et al., 1995) and acetylation (Murray & Shaw, 1997),
respectively, at this position. Therefore, we hoped that
increased DraE speciﬁcity could be gained from substitution
at the primary hydroxyl group; unfortunately, the CLS succi-
nate in this study did not ﬁt the surface with a single confor-
mation and alternative substituents to the succinyl moiety will
need exploring. In addition, the disordered nitrobenzene
group in the DraE–CLS structure in space group C2 implies
that the interaction with DraE is focused on the burial of the
chlorines rather than the benzene ring. This raises the possi-
bility that the nitrobenzene group is not required for DAF
inhibition. Conversely, in the CLM–ribosome complexes the
interaction is focused on the burial of the benzene ring and not
the chlorines (Hansen et al., 2003; Schlunzen et al., 2001).
DraE speciﬁcity could therefore be gained by modifying the
aromatic ring or by dispensing with it altogether. However,
although the nitrobenzene group is not required to bind to
DraE, it may be important for inhibition. Therefore, func-
tional studies are necessary to determine the precise
requirements for drug inhibition with regard to the aromatic
ring.
4.2. The CLM-binding pocket is able to accommodate bulkier
substituents
The BRM structure demonstrates that the CLM-binding
pocket of DraE is able to accommodate larger substituents on
the N-acyl group. This raises the possibility that a more
hydrophobic molecule could be used to displace the Met88
side chain from the binding pocket of AfaE-III, thereby
providing a means of inhibiting Afa-III and the Dr haem-
agglutinin. In this respect, the structure of an AfaE-III–BRM
complex would be highly informative. However, our attempts
to resolve this have so far been unsuccessful.
4.3. Possible mechanisms of chloramphenicol inhibition
A major obstacle to the design of an effective Dr adhesin
inhibitor is our lack of understanding of the mechanism of
DAF inhibition. CLM binds to a region of DraE that is
involved in binding to CEA (Korotkova, Cota et al., 2006) and
possibly type IV collagen (Carnoy & Moseley, 1997),
suggesting that CLM acts as a competitive inhibitor of both
these receptor interactions. However, the attenuation of DAF
binding is more puzzling. Mutagenesis (Van Loy et al., 2002),
surface plasmon resonance (Korotkova, Le Trong et al., 2006)
and NMR chemical shift mapping (Anderson et al., 2004)
studies have enabled the primary DAF-binding site to be
identiﬁed as a negatively charged depression on a surface of
DraE that is remote from the CLM-binding site (Fig. 4).
Therefore, CLM must act as a noncompetitive inhibitor of
DAF binding. This raises two possible mechanisms for DAF
inhibition by CLM: either the small molecule disturbs the
binding site indirectly and prevents rigid-body association or
it prevents the conformational equilibrium of DraE from
being pulled towards the DAF-bound state. The former
possibility can be discounted, since CLM creates only local
perturbations that do not involve residues implicated in DAF
binding (Pettigrew et al., 2004). The latter possibility is
supported by the observation that DAF induces structural
perturbations throughout the entire AfaE-III–DSC molecule
(Anderson et al., 2004). Therefore, CLM may lock DraE in its
isolated solution state, thereby preventing it from undergoing
the ‘induced-ﬁt’ modiﬁcations required for DAF interaction.
The structure of DraE bound to DAF would potentially offer
new insights into how CLM inhibits noncompetitively. This
would greatly facilitate our search for a more potent and
speciﬁc Dr adhesin inhibitor.
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